Search clinical trials for: Salmeterol

Total 382 results

Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder in COPD

Pulmonary Disease, Chronic Obstructive

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, South Africa, Sweden
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, Sweden
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Healthy
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Neovii Biotech
Fresenius Biotech North America

Completed

Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy

Ovarian Cancer

United States
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
University of Dundee

Completed

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma (CLE001)

Asthma

United Kingdom
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Neothetics, Inc

Completed

Dose Ranging Study (RESET)

Periumbilical Subcutaneous Adipose Tissue Reduction

United States
GlaxoSmithKline

Completed

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Asthma
University of Miami
GlaxoSmithKline

Completed

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

Asthma
Boehringer Ingelheim

Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Pulmonary Disease, Chronic Obstructive

Austria, Canada, France, Germany, Italy, Russian Federation, Sweden
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol

Asthma

United States
University of Sussex

Completed

Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma (PACT)

Asthma

United Kingdom
Johns Hopkins University
GlaxoSmithKline; American Lung Association

Completed

Long-acting Beta Agonist Step Down Study (LASST)

Asthma

United States
GlaxoSmithKline

Completed

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
Università degli Studi di Ferrara
GlaxoSmithKline

Completed

Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD

Chronic Obstructive Pulmonary Disease

Italy
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

Bronchial Asthma

Japan
Centre Hospitalier Universitaire de Nīmes

Completed

Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis (PSORTI-BIO)

Psoriasis

France
Neothetics, Inc

Completed

Dose-ranging Study (LIPO-102-CL-11)

Abdominal Contour Defects

United States
Far Eastern Memorial Hospital
Research Ethics Review Committee

Unknown

Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients

Quality of Life | Percentage of Annual Acute Exacerbation

Taiwan
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Far Eastern Memorial Hospital

Unknown

Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Taiwan
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease Endpoints Study

Pulmonary Disease, Chronic Obstructive

Russian Federation, United States, Estonia, Chile
Boehringer Ingelheim

Completed

Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
National Jewish Health
GlaxoSmithKline

Terminated

Evaluating Genes in Sputum to Measure Drug Response in COPD

Emphysema | Chronic Obstructive Pulmonary Disease (COPD) | Chronic Bronchitis

United States
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
University of Rostock
GlaxoSmithKline

Completed

Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

Allergic Asthma

Germany
GlaxoSmithKline

Terminated

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Tiotropium and Salmeterol PK Study in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
GlaxoSmithKline

Completed

Viapaed Study In Children And Adolescents With Asthma

Asthma

Germany
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders
GlaxoSmithKline

Completed

Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).

Asthma

Australia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

Asthma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS) (MARS)

Asthma

United States
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
University of Copenhagen

Completed

Pharmacological Properties of Salmeterol

Pharmacokinetics in Healthy Young Men

Denmark
GlaxoSmithKline

Completed

Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States

3

Subscribe